ATNM — Actinium Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- $201.95m
- $125.31m
- $0.08m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 1.14 | 1.03 | 0.081 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Total Operating Expenses | 22.1 | 22.4 | 26.1 | 35.1 | 52 |
Operating Profit | -22.1 | -22.4 | -25 | -34.1 | -51.9 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -21.9 | -22.2 | -24.8 | -33 | -48.8 |
Net Income After Taxes | -21.9 | -22.2 | -24.8 | -33 | -48.8 |
Net Income Before Extraordinary Items | |||||
Net Income | -21.9 | -22.2 | -24.8 | -33 | -48.8 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -21.9 | -22.2 | -24.8 | -33 | -48.8 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -4.4 | -1.83 | -1.2 | -1.37 | -1.83 |